Clinical Trial Update: Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating paclitaxel and carboplatin with durvalumab, with or without oleclumab, as first-line therapy for previously untreated loca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Durvalumab (durvalumab)
• Oleclumab (oleclumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Jules Bordet Institute | Conditions: Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING